Compare ADMA Biologics Inc (ADMA) vs Tidewater Inc (TDW) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Tidewater (TDW) trades at $68.19, up 0.1% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. Recent earnings misses in Q1 2026 and Q4 2025 contrast with strong 2025 profitability, including a 22.16% net income margin and 24.03% ROE. The company reported $1.35B revenue in 2025, with net income of $334.66M, though 2026 projections indicate a slight decline. Positive cash flow from operations of $379.11M in 2025 supports financial health, while analyst sentiment remains cautious with a 'Hold' consensus.

Outlook: TDW's valuation appears reasonable with a P/E of 11.5 and EV/EBITDA of 8.52, but recent earnings volatility and a 61.54% analyst hold rating suggest near-term headwinds. Key risks include execution challenges amid declining revenue projections and competitive pressures in offshore marine services. Upside potential hinges on improved earnings consistency and sector recovery, while downside risks involve further profit margin compression and macroeconomic sensitivity.